Infinity Pharmaceuticals, Inc.
INFIQ · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $583 | $731 | $543 | $712 |
| % Growth | -20.2% | 34.6% | -23.7% | – |
| Cost of Goods Sold | $352 | $441 | $327 | $540 |
| Gross Profit | $231 | $290 | $216 | $172 |
| % Margin | 39.6% | 39.7% | 39.8% | 24.2% |
| R&D Expenses | $6,597 | $5,853 | $6,963 | $7,552 |
| G&A Expenses | $3,754 | $5,944 | $2,791 | $0 |
| SG&A Expenses | $3,754 | $5,944 | $2,791 | $3,501 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10,351 | $11,797 | $9,754 | $11,053 |
| Operating Income | -$10,120 | -$11,507 | -$9,538 | -$10,881 |
| % Margin | -1,735.8% | -1,574.1% | -1,756.5% | -1,528.2% |
| Other Income/Exp. Net | $164 | $462 | $308 | $164 |
| Pre-Tax Income | -$9,956 | -$11,045 | -$9,230 | -$10,717 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9,956 | -$11,045 | -$9,230 | -$10,717 |
| % Margin | -1,707.7% | -1,510.9% | -1,699.8% | -1,505.2% |
| EPS | -0.11 | -0.12 | -0.1 | -0.12 |
| % Growth | 8.3% | -20% | 16.7% | – |
| EPS Diluted | -0.11 | -0.12 | -0.1 | -0.12 |
| Weighted Avg Shares Out | 89,885 | 89,413 | 89,387 | 89,392 |
| Weighted Avg Shares Out Dil | 89,885 | 89,413 | 89,387 | 89,392 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $45 | $45 | $45 | $45 |
| Depreciation & Amortization | $106 | $105 | $106 | $111 |
| EBITDA | -$9,805 | -$10,895 | -$9,079 | -$10,561 |
| % Margin | -1,681.8% | -1,490.4% | -1,672% | -1,483.3% |